DSS' Impact BioMedical announces strategic merger with Dr. Ashley's
Merger Agreement Details: DSS's subsidiary, Impact BioMedical, is set to merge with Dr. Ashleys through a reverse merger, creating a new entity named "Dr Ashleys Limited" that will be listed on the NYSE American. This merger aims to combine their pharmaceutical capabilities and accelerate the development of innovative therapies.
Ownership and Management Changes: The merger includes various equity alignment actions to simplify ownership, with Impact becoming a wholly-owned subsidiary of the newly formed company, which will be managed by Dr. Ashleys' team and governed by a new Board of Directors, pending shareholder and regulatory approvals.
Get Free Real-Time Notifications for Any Stock
Analyst Views on DSS
About DSS
About the author
MongoDB Shares Surge 31%; Check Out 20 Stocks Making Moves in Premarket Trading
MongoDB's Strong Performance: MongoDB, Inc. shares surged 31% in pre-market trading after reporting better-than-expected second-quarter results and raising its fiscal 2026 adjusted EPS guidance to between $3.64 and $3.73.
Other Gainers: Notable pre-market gainers included NovaBay Pharmaceuticals (up 66.7% due to a special cash dividend), Bollinger Innovations (up 32.1%), and BioXcel Therapeutics (up 19.5% after announcing Phase 3 data).
Pre-Market Losers: Stocks that declined in pre-market trading included Fenbo Holdings (down 16.8%), SCWorx Corp (down 15.2%), and Beneficient (down 14.3%).
Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting significant movements both upward and downward.
DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth
Financial Performance: DSS, Inc. reported a 28% year-over-year revenue growth in Q1 2025, driven by increased sales in printed products and rental income, alongside significant debt reduction and improved operating cash flow.
Strategic Focus: The company is committed to streamlining operations and enhancing shareholder value, with plans for continued development and potential mergers and acquisitions as it positions itself for growth in the latter half of 2025.
